.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
AstraZeneca
Moodys
Baxter
Chinese Patent Office
US Department of Justice
UBS
Fuji
Argus Health
Citi

Generated: November 21, 2017

DrugPatentWatch Database Preview

CARDIZEM Drug Profile

« Back to Dashboard

Which patents cover Cardizem, and what generic Cardizem alternatives are available?

Cardizem is a drug marketed by Valeant Intl, Biovail Labs Intl, and Biovail. and is included in six NDAs. There are two patents protecting this drug and two Paragraph IV challenges.

The generic ingredient in CARDIZEM is diltiazem hydrochloride. There are twenty-six drug master file entries for this compound. Forty-eight suppliers are listed for this compound. Additional details are available on the diltiazem hydrochloride profile page.
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Biovail
CARDIZEM SR
diltiazem hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL019471-004Jan 23, 1989DISCNYesNo► Subscribe► Subscribe► Subscribe
Valeant Intl
CARDIZEM
diltiazem hydrochloride
TABLET;ORAL018602-001Nov 5, 1982ABRXYesNo► Subscribe► Subscribe► Subscribe
Valeant Intl
CARDIZEM LA
diltiazem hydrochloride
TABLET, EXTENDED RELEASE;ORAL021392-003Feb 6, 2003ABRXYesNo► Subscribe► SubscribeY ► Subscribe
Valeant Intl
CARDIZEM LA
diltiazem hydrochloride
TABLET, EXTENDED RELEASE;ORAL021392-006Feb 6, 2003ABRXYesYes► Subscribe► SubscribeY ► Subscribe
Biovail
CARDIZEM
diltiazem hydrochloride
INJECTABLE;INJECTION020792-001Sep 5, 1997DISCNNoNo► Subscribe► Subscribe► Subscribe
Valeant Intl
CARDIZEM
diltiazem hydrochloride
TABLET;ORAL018602-004Dec 8, 1986ABRXYesYes► Subscribe► Subscribe► Subscribe
Valeant Intl
CARDIZEM CD
diltiazem hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL020062-005Aug 24, 1999AB3RXYesYes► Subscribe► Subscribe► Subscribe
Valeant Intl
CARDIZEM LA
diltiazem hydrochloride
TABLET, EXTENDED RELEASE;ORAL021392-004Feb 6, 2003ABRXYesNo► Subscribe► SubscribeY ► Subscribe
Valeant Intl
CARDIZEM CD
diltiazem hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL020062-001Aug 10, 1992AB3RXYesNo► Subscribe► Subscribe► Subscribe
Valeant Intl
CARDIZEM LA
diltiazem hydrochloride
TABLET, EXTENDED RELEASE;ORAL021392-004Feb 6, 2003ABRXYesNo► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: CARDIZEM

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Valeant Intl
CARDIZEM
diltiazem hydrochloride
TABLET;ORAL018602-001Nov 5, 1982► Subscribe► Subscribe
Valeant Intl
CARDIZEM
diltiazem hydrochloride
TABLET;ORAL018602-004Dec 8, 1986► Subscribe► Subscribe
Valeant Intl
CARDIZEM
diltiazem hydrochloride
TABLET;ORAL018602-004Dec 8, 1986► Subscribe► Subscribe
Valeant Intl
CARDIZEM
diltiazem hydrochloride
TABLET;ORAL018602-004Dec 8, 1986► Subscribe► Subscribe
Valeant Intl
CARDIZEM
diltiazem hydrochloride
TABLET;ORAL018602-003Dec 8, 1986► Subscribe► Subscribe
Valeant Intl
CARDIZEM
diltiazem hydrochloride
TABLET;ORAL018602-002Nov 5, 1982► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for CARDIZEM

Drugname Dosage Strength RLD Submissiondate
diltiazem hydrochlorideExtended-release Tablets120 mg, 180 mg, 240 mg, 300 mg and 360 mgCardizem LA8/30/2005
diltiazem hydrochlorideExtended-release Tablets420 mgCardizem LA4/25/2005
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Covington
Cerilliant
Medtronic
Fuji
Healthtrust
Cantor Fitzgerald
Federal Trade Commission
Argus Health
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot